...
首页> 外文期刊>Haematologica >Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors
【24h】

Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors

机译:ETV6中的种系变异导致血小板形成减少,血小板功能障碍和循环CD34 +祖细胞水平升高

获取原文
           

摘要

Variants in ETV6 , which encodes a transcription repressor of the E26 transformation-specific family, have recently been reported to be responsible for inherited thrombocytopenia and hematologic malignancy. We sequenced the DNA from cases with unexplained dominant thrombocytopenia and identified six likely pathogenic variants in ETV6 , of which five are novel. We observed low repressive activity of all tested ETV6 variants, and variants located in the E26 transformation-specific binding domain (encoding p.A377T, p.Y401N) led to reduced binding to corepressors. We also observed a large expansion of megakaryocyte colony-forming units derived from variant carriers and reduced proplatelet formation with abnormal cytoskeletal organization. The defect in proplatelet formation was also observed in control CD34~(+) cell-derived megakaryocytes transduced with lentiviral particles encoding mutant ETV6. Reduced expression levels of key regulators of the actin cytoskeleton CDC42 and RHOA were measured. Moreover, changes in the actin structures are typically accompanied by a rounder platelet shape with a highly heterogeneous size, decreased platelet arachidonic response, and spreading and retarded clot retraction in ETV6 deficient platelets. Elevated numbers of circulating CD34~(+) cells were found in p.P214L and p.Y401N carriers, and two patients from different families suffered from refractory anemia with excess blasts, while one patient from a third family was successfully treated for acute myeloid leukemia. Overall, our study provides novel insights into the role of ETV6 as a driver of cytoskeletal regulatory gene expression during platelet production, and the impact of variants resulting in platelets with altered size, shape and function and potentially also in changes in circulating progenitor levels.
机译:据报道,ETV6的变体编码E26转化特异性家族的转录阻遏物,与遗传性血小板减少症和血液系统恶性肿瘤有关。我们对来自无法解释的显性血小板减少症病例的DNA进行了测序,并在ETV6中鉴定出六个可能的致病变异,其中五个是新颖的。我们观察到所有测试的ETV6变体的低阻抑活性,并且位于E26转化特异性结合域(编码p.A377T,p.Y401N)的变体导致与corepressors的结合减少。我们还观察到衍生自变异携带者的巨核细胞集落形成单位的大量扩张,并减少了具有异常细胞骨架组织的血小板的形成。在由编码突变型ETV6的慢病毒颗粒转导的对照CD34〜(+)细胞衍生的巨核细胞中也观察到了血小板原形成的缺陷。肌动蛋白细胞骨架CDC42和RHOA的关键调控因子的表达水平降低了。此外,肌动蛋白结构的改变通常伴随着圆形的血小板形状,其具有高度不均一的大小,血小板花生四烯酸反应降低,以及ETV6缺陷型血小板中的血凝块扩张和延缓。在p.P214L和p.Y401N携带者中发现循环CD34〜(+)细胞数量增加,两名来自不同家庭的患者患有难治性贫血,并伴有大量母细胞,而来自第三家庭的一名患者已成功治疗急性髓性白血病。总体而言,我们的研究提供了关于ETV6在血小板生成过程中作为细胞骨架调节基因表达的驱动器的作用以及变体的影响的新颖见解,这些变异导致血小板的大小,形状和功能发生改变,还可能在循环祖细胞水平上发生变化。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号